Skip to main content
Top
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters

Authors: Ke Hao, John M Luk, Nikki PY Lee, Mao Mao, Chunsheng Zhang, Mark D Ferguson, John Lamb, Hongyue Dai, Irene O Ng, Pak C Sham, Ronnie TP Poon

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Surgical resection is one important curative treatment for hepatocellular carcinoma (HCC), but the prognosis following surgery differs substantially and such large variation is mainly unexplained. A review of the literature yields a number of clinicopathologic parameters associated with HCC prognosis. However, the results are not consistent due to lack of systemic approach to establish a prediction model incorporating all these parameters.

Methods

We conducted a retrospective analysis on the common clinicopathologic parameters from a cohort of 572 ethnic Chinese HCC patients who received curative surgery. The cases were randomly divided into training (n = 272) and validation (n = 300) sets. Each parameter was individually tested and the significant parameters were entered into a linear classifier for model building, and the prediction accuracy was assessed in the validation set

Results

Our findings based on the training set data reveal 6 common clinicopathologic parameters (tumor size, number of tumor nodules, tumor stage, venous infiltration status, and serum α-fetoprotein and total albumin levels) that were significantly associated with the overall HCC survival and disease-free survival (time to recurrence). We next built a linear classifier model by multivariate Cox regression to predict prognostic outcomes of HCC patients after curative surgery This analysis detected a considerable fraction of variance in HCC prognosis and the area under the ROC curve was about 70%. We further evaluated the model using two other protocols; leave-one-out procedure (n = 264) and independent validation (n = 300). Both were found to have excellent prediction power. The predicted score could separate patients into distinct groups with respect to survival (p-value = 1.8e-12) and disease free survival (p-value = 3.2e-7).

Conclusion

This described model will provide valuable guidance on prognosis after curative surgery for HCC in clinical practice. The adaptive nature allows easy accommodation for future new biomarker inputs, and it may serve as the foundation for future modeling and prediction for HCC prognosis after surgical treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bosch FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis. 1999, 19 (3): 271-285.CrossRefPubMed Bosch FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis. 1999, 19 (3): 271-285.CrossRefPubMed
2.
go back to reference Kim JH, Choi MS, Lee H, Kim do Y, Lee JH, Koh KC, Yoo BC, Paik SW, Rhee JC: Clinical features and prognosis of hepatocellular carcinoma in young patients from a hepatitis B-endemic area. J Gastroenterol Hepatol. 2006, 21 (3): 588-594.CrossRefPubMed Kim JH, Choi MS, Lee H, Kim do Y, Lee JH, Koh KC, Yoo BC, Paik SW, Rhee JC: Clinical features and prognosis of hepatocellular carcinoma in young patients from a hepatitis B-endemic area. J Gastroenterol Hepatol. 2006, 21 (3): 588-594.CrossRefPubMed
3.
go back to reference Lam VW, Ng KK, Chok KS, Cheung TT, Yuen J, Tung H, Tso WK, Fan ST, Poon RT: Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg. 2008, 207 (1): 20-29.CrossRefPubMed Lam VW, Ng KK, Chok KS, Cheung TT, Yuen J, Tung H, Tso WK, Fan ST, Poon RT: Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg. 2008, 207 (1): 20-29.CrossRefPubMed
4.
go back to reference Lau WY, Lai EC: Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int. 2008, 7 (3): 237-257.PubMed Lau WY, Lai EC: Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int. 2008, 7 (3): 237-257.PubMed
5.
go back to reference Sandhu DS, Tharayil VS, Lai JP, Roberts LR: Treatment options for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2008, 2 (1): 81-92.CrossRefPubMed Sandhu DS, Tharayil VS, Lai JP, Roberts LR: Treatment options for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2008, 2 (1): 81-92.CrossRefPubMed
6.
go back to reference Midorikawa Y, Makuuchi M, Tang W, Aburatani H: Microarray-based analysis for hepatocellular carcinoma: from gene expression profiling to new challenges. World J Gastroenterol. 2007, 13 (10): 1487-1492.CrossRefPubMedPubMedCentral Midorikawa Y, Makuuchi M, Tang W, Aburatani H: Microarray-based analysis for hepatocellular carcinoma: from gene expression profiling to new challenges. World J Gastroenterol. 2007, 13 (10): 1487-1492.CrossRefPubMedPubMedCentral
7.
go back to reference Stany MP, Bonome T, Wamunyokoli F, Zorn K, Ozbun L, Park DC, Hao K, Boyd J, Sood AK, Gershenson DM, et al: Classification of ovarian cancer: a genomic analysis. Adv Exp Med Biol. 2008, 622: 23-33.CrossRefPubMed Stany MP, Bonome T, Wamunyokoli F, Zorn K, Ozbun L, Park DC, Hao K, Boyd J, Sood AK, Gershenson DM, et al: Classification of ovarian cancer: a genomic analysis. Adv Exp Med Biol. 2008, 622: 23-33.CrossRefPubMed
8.
go back to reference Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, et al: Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008, 822-7. 8 Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, et al: Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008, 822-7. 8
9.
go back to reference Chiriva-Internati M, Grizzi F, Wachtel MS, Jenkins M, Ferrari R, Cobos E, Frezza EE: Biological treatment for liver tumor and new potential biomarkers. Dig Dis Sci. 2008, 53 (3): 836-843.CrossRefPubMed Chiriva-Internati M, Grizzi F, Wachtel MS, Jenkins M, Ferrari R, Cobos E, Frezza EE: Biological treatment for liver tumor and new potential biomarkers. Dig Dis Sci. 2008, 53 (3): 836-843.CrossRefPubMed
10.
go back to reference Esnaola NF, Lauwers GY, Mirza NQ, Nagorney DM, Doherty D, Ikai I, Yamaoka Y, Regimbeau JM, Belghiti J, Curley SA, et al: Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg. 2002, 6 (2): 224-232. discussion 232CrossRefPubMed Esnaola NF, Lauwers GY, Mirza NQ, Nagorney DM, Doherty D, Ikai I, Yamaoka Y, Regimbeau JM, Belghiti J, Curley SA, et al: Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg. 2002, 6 (2): 224-232. discussion 232CrossRefPubMed
11.
go back to reference Collette S, Bonnetain F, Paoletti X, Doffoel M, Bouche O, Raoul JL, Rougier P, Masskouri F, Bedenne L, Barbare JC: Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol. 2008, 19 (6): 1117-1126.CrossRefPubMed Collette S, Bonnetain F, Paoletti X, Doffoel M, Bouche O, Raoul JL, Rougier P, Masskouri F, Bedenne L, Barbare JC: Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol. 2008, 19 (6): 1117-1126.CrossRefPubMed
12.
go back to reference Ng IO, Lai EC, Fan ST, Ng MM, So MK: Prognostic significance of pathologic features of hepatocellular carcinoma. A multivariate analysis of 278 patients. Cancer. 1995, 76 (12): 2443-2448.CrossRefPubMed Ng IO, Lai EC, Fan ST, Ng MM, So MK: Prognostic significance of pathologic features of hepatocellular carcinoma. A multivariate analysis of 278 patients. Cancer. 1995, 76 (12): 2443-2448.CrossRefPubMed
13.
go back to reference Heagerty PJ, Lumley T, Pepe MS: Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000, 56 (2): 337-344.CrossRefPubMed Heagerty PJ, Lumley T, Pepe MS: Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000, 56 (2): 337-344.CrossRefPubMed
14.
go back to reference Benzoni E, Lorenzin D, Favero A, Adani G, Baccarani U, Molaro R, Zompicchiatti A, Saccomano E, Avellini C, Bresadola F, et al: Liver resection for hepatocellular carcinoma: a multivariate analysis of factors associated with improved prognosis. The role of clinical, pathological and surgical related factors. Tumori. 2007, 93 (3): 264-268.PubMed Benzoni E, Lorenzin D, Favero A, Adani G, Baccarani U, Molaro R, Zompicchiatti A, Saccomano E, Avellini C, Bresadola F, et al: Liver resection for hepatocellular carcinoma: a multivariate analysis of factors associated with improved prognosis. The role of clinical, pathological and surgical related factors. Tumori. 2007, 93 (3): 264-268.PubMed
15.
go back to reference Poon RT, Ng IO, Fan ST, Lai EC, Lo CM, Liu CL, Wong J: Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol. 2001, 19 (12): 3037-3044.PubMed Poon RT, Ng IO, Fan ST, Lai EC, Lo CM, Liu CL, Wong J: Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol. 2001, 19 (12): 3037-3044.PubMed
16.
go back to reference Giannelli G, Antonaci S: Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice. J Clin Gastroenterol. 2006, 40 (9): 842-846.CrossRefPubMed Giannelli G, Antonaci S: Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice. J Clin Gastroenterol. 2006, 40 (9): 842-846.CrossRefPubMed
17.
go back to reference Chen JY, Chau GY, Lui WY, Tsay SH, King KL, Wu CW: Clinicopathologic features and factors related to survival of patients with small hepatocellular carcinoma after hepatic resection. World J Surg. 2003, 27 (3): 294-298.CrossRefPubMed Chen JY, Chau GY, Lui WY, Tsay SH, King KL, Wu CW: Clinicopathologic features and factors related to survival of patients with small hepatocellular carcinoma after hepatic resection. World J Surg. 2003, 27 (3): 294-298.CrossRefPubMed
18.
go back to reference Wayne JD, Lauwers GY, Ikai I, Doherty DA, Belghiti J, Yamaoka Y, Regimbeau JM, Nagorney DM, Do KA, Ellis LM, et al: Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg. 2002, 235 (5): 722-730. discussion 730-721CrossRefPubMedPubMedCentral Wayne JD, Lauwers GY, Ikai I, Doherty DA, Belghiti J, Yamaoka Y, Regimbeau JM, Nagorney DM, Do KA, Ellis LM, et al: Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg. 2002, 235 (5): 722-730. discussion 730-721CrossRefPubMedPubMedCentral
19.
go back to reference Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, Curley SA, Ellis LM, Regimbeau JM, Rashid A, et al: Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002, 20 (6): 1527-1536.CrossRefPubMed Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, Curley SA, Ellis LM, Regimbeau JM, Rashid A, et al: Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002, 20 (6): 1527-1536.CrossRefPubMed
20.
go back to reference Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999, 19 (3): 329-338.CrossRefPubMed Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999, 19 (3): 329-338.CrossRefPubMed
21.
go back to reference Yau T, Yao TJ, Chan P, Ng K, Fan ST, Poon RT: A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials. Cancer. 2008, 113 (10): 2742-2751.CrossRefPubMed Yau T, Yao TJ, Chan P, Ng K, Fan ST, Poon RT: A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials. Cancer. 2008, 113 (10): 2742-2751.CrossRefPubMed
22.
go back to reference Llovet JM, Fuster J, Bruix J: The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004, 10 (2 Suppl 1): S115-120.CrossRefPubMed Llovet JM, Fuster J, Bruix J: The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004, 10 (2 Suppl 1): S115-120.CrossRefPubMed
23.
go back to reference Fukuda S, Itamoto T, Amano H, Kohashi T, Ohdan H, Tashiro H, Asahara T: Clinicopathologic features of hepatocellular carcinoma patients with compensated cirrhosis surviving more than 10 years after curative hepatectomy. World J Surg. 2007, 31 (2): 345-352.CrossRefPubMed Fukuda S, Itamoto T, Amano H, Kohashi T, Ohdan H, Tashiro H, Asahara T: Clinicopathologic features of hepatocellular carcinoma patients with compensated cirrhosis surviving more than 10 years after curative hepatectomy. World J Surg. 2007, 31 (2): 345-352.CrossRefPubMed
24.
go back to reference Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, et al: Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006, 10 (2): 99-111.CrossRefPubMed Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, et al: Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006, 10 (2): 99-111.CrossRefPubMed
25.
go back to reference Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, et al: Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. N Engl J Med. 2008, 6;359 (19): 1995-2004.CrossRef Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, et al: Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. N Engl J Med. 2008, 6;359 (19): 1995-2004.CrossRef
Metadata
Title
Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters
Authors
Ke Hao
John M Luk
Nikki PY Lee
Mao Mao
Chunsheng Zhang
Mark D Ferguson
John Lamb
Hongyue Dai
Irene O Ng
Pak C Sham
Ronnie TP Poon
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-389

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine